title: Intradetrusor onabotulinumtoxinA for overactive bladder.
abstract: BACKGROUND
  Overactive bladder is a life-compromising disease that affects approximately 11.8% of all men and women, with increasing rates in the elderly. The mainstay of pharmacotherapy for this disease, anticholinergics, has up to a 71% discontinuation rate at 6 months. The emerging data of intradetrusor onabotulinumtoxinA (onabotA) use for treatment of idiopathic overactive bladder is showing to be an efficacious and well-tolerated alternative to the mainstay of therapy.
  
  
  METHODS
  This study covers the use of onabotA and its use for idiopathic overactive bladder, stemming from its use in neurogenic detrusor overactivity, by evaluating the conclusions of current studies. A literature search and review was carried out for onabotA in treatment of overactive bladder using PubMed.
  
  
  CONCLUSIONS
  Multiple randomized clinical trials have shown that intradetrusor injection with onabotA is effective in treating non-neurogenic bladder with promising efficacy in patients who have failed traditional pharmacotherapy. This treatment may be superior in certain patients due to its higher rate of compliance and higher rates of complete symptom resolution. Long-term studies are needed.
authors.affiliation: Vanderbilt University Medical Center, Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology , B-1100 Medical Center North, Nashville, TN 37232 , USA +1 615 322 8968 ; +1 615 343 8881 ; lisa.h.jambusaria@vanderbilt.edu.
authors.forename: Lisa H
authors.initials: LH
authors.lastname: Jambusaria
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D019274:Botulinum Toxins, Type A